Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Clinical trial NCT05627427 · UNKNOWN

Trial details

NCT number: NCT05627427
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Neuroendocrine Tumor Grade 3 Neuroendocrine Carcinoma Pancreatic Carcinoma

Start date: 2022-07-01
Primary completion: 2024-04-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.